PH12022550360A1 - Tetracyclic compounds and their salts, compositions, and methods for their use - Google Patents

Tetracyclic compounds and their salts, compositions, and methods for their use

Info

Publication number
PH12022550360A1
PH12022550360A1 PH1/2022/550360A PH12022550360A PH12022550360A1 PH 12022550360 A1 PH12022550360 A1 PH 12022550360A1 PH 12022550360 A PH12022550360 A PH 12022550360A PH 12022550360 A1 PH12022550360 A1 PH 12022550360A1
Authority
PH
Philippines
Prior art keywords
salts
compositions
methods
tetracyclic compounds
methyl
Prior art date
Application number
PH1/2022/550360A
Other languages
English (en)
Inventor
John Soong
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of PH12022550360A1 publication Critical patent/PH12022550360A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH1/2022/550360A 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use PH12022550360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886621P 2019-08-14 2019-08-14
US201962946774P 2019-12-11 2019-12-11
PCT/US2020/046329 WO2021030671A1 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Publications (1)

Publication Number Publication Date
PH12022550360A1 true PH12022550360A1 (en) 2023-02-27

Family

ID=74568302

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550360A PH12022550360A1 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Country Status (12)

Country Link
US (1) US20210046071A1 (enExample)
EP (1) EP4013421A4 (enExample)
JP (1) JP7566010B2 (enExample)
KR (1) KR20220130085A (enExample)
CN (1) CN114599368A (enExample)
AU (1) AU2020328590B2 (enExample)
BR (1) BR112022002784A2 (enExample)
CA (1) CA3151112A1 (enExample)
IL (1) IL290626A (enExample)
PH (1) PH12022550360A1 (enExample)
TW (1) TW202114694A (enExample)
WO (1) WO2021030671A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101601332B1 (ko) * 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
EP3074391B1 (en) * 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
CN119185322A (zh) * 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
ES2959536T3 (es) 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
EP3752149A4 (en) * 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE

Also Published As

Publication number Publication date
JP2022544559A (ja) 2022-10-19
CN114599368A (zh) 2022-06-07
EP4013421A1 (en) 2022-06-22
WO2021030671A1 (en) 2021-02-18
IL290626A (en) 2022-04-01
AU2020328590B2 (en) 2026-03-26
BR112022002784A2 (pt) 2022-08-09
KR20220130085A (ko) 2022-09-26
CA3151112A1 (en) 2021-02-18
EP4013421A4 (en) 2023-08-23
US20210046071A1 (en) 2021-02-18
TW202114694A (zh) 2021-04-16
AU2020328590A1 (en) 2022-03-10
JP7566010B2 (ja) 2024-10-11

Similar Documents

Publication Publication Date Title
MX2025002170A (es) Inhibidores de kras g12c
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PH12022551574A1 (en) Egfr inhibitors
CR20200376A (es) Inhibidores de cd73
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
ATE440603T1 (de) 8-hydroxychinolinderivate
GEP20084341B (en) Aminoheteroaryl compounds as protein kinase inhibitors
GEP20125589B (en) TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
PH12022551241A1 (en) Egfr inhibitors
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
WO2019168688A3 (en) Quinolone analogs and their salts, compositions, and method for their use
ZA202103132B (en) Ketamine pamoate and use thereof
GEAP202415849A (en) Crystalline salt forms of kinase inhibitor
BR112022002784A2 (pt) Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo
PH12021552953A1 (en) Tricyclic compounds
MX2021005944A (es) Inhibidores de rip1.
MX2025013372A (es) Inhibidores de gsk3\03b1 y metodos de uso de estos
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.